FOLH1 and neoplasm: The availability of tumor-associated antigens in urinary system tumors, such as prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), and epidermal growth factor receptor (EGFR), makes CAR T cell therapy possible for urinary system tumors.